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DOSE-REDUCED CONDITIONING WITH FLUDARABINE/MELPHALAN 
FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION FOR 
PATIENTS WITH ADVANCED STAGE II/111 MULTIPLE MYELOMA 
K:rbger, N.M.~; ShimoM, A.3; Nagler, A.s; Say'r, H.G.4; Schw- 
erdtfeger, R. 7; tliehl, ~I. ~; Vv%tkozt,sky, G. 7; H;andt, H. 1; Rellges, 
H.e; Ayuk, F.e; Zabelina, T.2; Zallder, A.R. e 1. Bo*le Marrow 
Transplantatioll, University Hospital, Hamb~trg, Ge,wlalu; 2. Bone 
Mar'rozv Tralzsplantatioll Chai~lz Sheba Medical Cellter, Tel 
Hashomer, Israel; 3. Bone Marrow Tvansplantatiotl, Ulliversity 
Hospital, Jell& Gerlnany; 4. Departllzent of Hematology, AK St. 
Geol~g, Hamburg, Gelmlal~y; Y. Bone Marrozu Transplantatiol~, 
idar Oberstei~z, GelwlaJo,; 6. Bogle 3'Imv'ow Tl'alzsplalltatiotl, DKD 
Cl#zic, ~Viesbadell, Ge*'lllalzy; 7. Bolle Marrozv Trallwlalltatiolz , 
Niirnberg, GerTtmny. 
Sixty-four patients (pts) with advanced stage II/III nmltiple 
myeloma received a dose-reduced conditioning consisting of 
melphalan (100-140 mg/qm) and fludarabine (90-180 mg/qm) 
followed by related (n=36) or unrelated (n=28) allogeneic stem 
cell transplantation. Fifty-two pts additionally received amedian 
of 30 mg/kg anti-thymocyte globulin (ATG Fresenins, Ger- 
many). Further GvHD-prophylaxis consisted of CSA and short 
course MTX (n=62) or CSA plus MMF (n=2). All pts received at 
least one prior high-close chemotherapy followed by autologous 
(n= 63) or allogeneic (n=l) transplantation, i  27 pts as part of 
an autologous-allogeneic tandem protocol. The median age of 
the pts was 51 years (range 32-64). The median serum level of 
beta-2-microglobulin was 3 mg/dl (range 1, 3 - 8). Stem cell 
source was PBSC in 57 and BM in 7 cases. The median trans- 
planted cell dose was 5.1 x106 CD34+ cells/kg. Sixty-three pts 
(97%) engrafted with ANC > 1 xl09/L after a median of I6 
days (r, 10-24). Acute GvHD grade II- IV was seen in 39%, 
severe grade III/IV in 16% of the patients. Limited and exten- 
sive chronic GvHD were noted in 25% and 22%, respectively. 
The treatment related mortality at one year was 23%, mainly 
due to GvHD (n-4) and infectious complications (n=4). After 
allografting 45% of the pts achieved a complete remission with 
negative immunofixation, while 45% achieved a partial rentis- 
sion, resulting in an overall response rate of 90%. After a medi- 
an follow-up of 12 months, the 2 years estimated overall and 
progression-free survival is 55% (95% CI: 35-75%) and 38% 
(95% CI: 20- 56%), respectively. There was no difference in OS 
survival between related and unrelated onors (56 vs 55%), but 
a trend for better OS in patients transplanted without relapse 
(tandem auto-allo) after HD-chemotherapy (61 vs 41%, n.s.) 
and in patients without Del 13 in FISH analysis (78 vs 30%, 
n.s.). Melphalan/fludarabine based dose-reduced conditioning 
followed by allogeneic stem cell transplantation from related 
and unrelated onors induces high remission rate with accept- 
able toxicity. 
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NORMAL HEMATOPOIETIC STEM CELL FUNCTION IN MICE FOLLOW- 
ING TREATMENT WITH BORTEZOMIB 
Fitzge~,ld, M.; tiraser, C.; V/ebb, I.; Schellkein, D.; Esselt#le, D.; 
147eicb, N.S. Millelmilml Pha~wmceuticals b c., Gi~Hbridge, MA. 
Bortezolnib (VELCADE TM), formerly PS-341, is a novel 
proteasome inhibitor being evaluated in a randomized trial in 
patients with multiple myeloma, a disease frequently treated 
with autologous tem cell transplantation. Conventional cyto- 
toxic agents have been shown to negatively affect hematopoi- 
etic stem cell function in patients undergoing autologous 
transplantation. In order to determine whether bortezomib 
produces similar effects on hematopoiet ic stem cells, we 
assessed whether treatment with bortezomib affected progeni- 
tor derived colony growth and engraftment in a murine bone 
marrow transplantation model. C57BL/6 mice were treated 
with four 21 day cycles of saline or bortezomib consisting of 
administration of drug or saline on days 1, 4, 8 and 11 fol- 
lowed by a 10 day rest period. Following treatment, bone 
marrow cells were harvested from femurs and tibias. The cells 
were used for hematopoietic progenitor cell assays (CFU-GM, 
Poster  P resentat ions  - Sess ion  I I  
CFU-E, and HPP-CFC assays) and for transplantation i to 
lethally irradiated B6.SJL recipient mice. There was no differ- 
ence observed in the nmnber of hematopoietic bone marrow 
progenitor cells from saline or bortezomib treated animals in 
the in vitro assays performed. FACS analysis revealed no dif- 
ference in the engraftment of donor derived bone marrow 
cells transplanted from saline or bortezomib treated animals. 
The peripheral blood cell counts of animals transplanted with 
marrow fronl either saline treated or bortezomib treated ani- 
mals were compared. No difference was observed in the 
recovery of platelets, white blood cells, neutrophils, lympho- 
cytes, monocytes, eosinophils, basophils red blood cells, 
hemoglobin, hematocrit or reticulocytes. We conclude that 
bortezomib did not adversely affect murine hematopoietic 
stem ceils in this study. Successful peripheral blood stem cell 
mobilization has been reported in multiple myeloma patients 
treated with bortezomib and data is being collected in ongo- 
ing clinical trials. 
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IDIOTYPE VACCINATION FOLLOWING HIGH DOSE CHEMOTHERAPY 
+ AUTOLOGOUS STEM CELL TRANSPLANT IN INDOLENT AND MAN- 
TLE CELL LYMPHOMA 
Hohnmz, P.R.I; Bashey, A.S; Ca*v'ier, E. 1, Corringham, $3; Davis, 
B.S; Oblon, D.S; C,~en, if.s; Gold, D/;  k/h6 X..~-; Ball, E. l 1. Ullivel'si 
ty of California, Sills Diego, San Diego, CA; 2. Favrille bzc., Sail 
Diego, CA. 
Cell-surface idiotype (Id) of indolent lymphoma patients is a 
specific tumor marker. Strategies to enhance immune recogni- 
tion of Id have been attempted. Promising responses have b en 
obtained in patients with lower tumor bulk at time of vaccina- 
tion. This study evaluates Id complexed to keyhole limpet hemo- 
cyanin (KLH) administered with GM-CSF following autologous 
transplantation (ASCT). Patient specific Id is produced as intact 
recombinant antibody. Cellular and humoral responses (IR) of 4 
patients completing treatment (5 vaccinations over 6 months), 
commencing at least 3 months post-ASCT are reported. Toxici- 
ties probably or possibly related to therapy and/or GM-CSF 
include: Grade 1 chills/rigors, itchy/watery eyes, nausea, a~llary 
soreness, sternal discomfort, generalized body aches, and joint 
stiffness; Grade 2 injection site reaction, headache, fatigue, 
blurred vision; and Grade 3 leukopenia (present pre-vaccina- 
tion). Anti-KLH antibody and anti-Id titers were evaluated 
(ELISA). After 2 vaccine treatments, patients 1 & 2 developed 
significant levels of anti-KLH (IgM and IgG1). Neither mantle 
cell patients developed anti-KLH. After 4 treatments patient #~ 
developed anti-KLH. Patients l&3 made significant levels of 
specific anti-Id antibody co-incident with high titer anti-KLH. 
Patient #2 made non-specific antibody responses. For Id specific 
cell mediated innnunity PBMCs from patients #1-3 were cul- 
tured with either KLH, patient derived recombinant id or con 
trol Id. After 5 days cells were stained for surface expression of 
CD4 and CD25 and for cytoplasmic expression of TNF-alpha 
and interferon gamma. All three patients made sustained CD4+ 
anti-KLH T cell responses detectable at 1 month post vaccine 
#1. Patients I&3 also made specific anti-Id T cell responses. 
Patient #2 made a specific anti-Id T cell response after vaccine 
#5. Patient #4 has not been assessed for T cell responses . These 
results suggest hat humoraI and cellular immune responses can 
be rapidly induced in indolent and mantle cell lymphoma 
patients following ASCT supporting the evaluation of Id vac- 
cines in this setting. 
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